Evidence map›Paper›PMID 37513194›Full record

ArticleMolecules (Basel, Switzerland)2023

In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease.

Menghan Gao, Dongwei Kang, Na Liu, Yanna Liu

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Structural modifications and kinetic effects ofFrontiers in molecular biosciences · 2024
    Article
  3. In-silico analysis of potent Mosquirix vaccine adjuvant leads.Journal, genetic engineering & biotechnology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Menghan GaoSchool of Pharmacy and Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, 6699 Qingdao Road, Jinan 250117, China.
Dongwei KangDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan 250012, China.ORCID 0000-0001-9232-953X
Na LiuDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan 250012, China.ORCID 0000-0002-3274-5416
Yanna LiuSchool of Pharmacy and Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, 6699 Qingdao Road, Jinan 250117, China.ORCID 0000-0002-5017-5728
Shandong First Medical University · CNShandong University · CN

Funding

Academic Promotion Program of Shandong First Medical University 2019LJ003
6 · The paper itself

Abstract

The COVID-19 pandemic has caused severe health threat globally, and novel SARS-Cov-2 inhibitors are urgently needed for antiviral treatment. The main protease (M

Indexed as

COVID-19Antiviral AgentsCoronavirus 3C ProteasesHumansMolecular Docking SimulationMolecular Dynamics SimulationPandemicsProtease InhibitorsSARS-CoV-23C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesProtease Inhibitorsmain protease inhibitorsMD simulationmolecular docking-based virtual screeningSARS-CoV-2

Identifiers

PMID37513194
PMCPMC10383128
OpenAlexW4383878175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.